FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2794357789> ?p ?o ?g. }

• W2794357789 endingPage "953" @default.
• W2794357789 startingPage "945" @default.
• W2794357789 abstract "Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD Gary T Ferguson,1 Roberto Rodriguez-Roisin,2 Colin Reisner,3,4 Andrea Maes,3 Shahid Siddiqui,4 Ubaldo J Martin4 1Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USA; 2Universitat de Barcelona, Hospital Clínic-The August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; 3Pearl – A member of the AstraZeneca Group, Morristown, NJ, USA; 4AstraZeneca, Gaithersburg, MD, USA Purpose: The efficacy and tolerability of GFF MDI (Bevespi Aerosphere®), a fixed-dose combination of glycopyrronium (GP)/formoterol fumarate dihydrate (FF) 14.4/10 µg (equivalent to glycopyrrolate/formoterol fumarate 18/9.6 µg) delivered by metered dose inhaler (MDI) using innovative co-suspension delivery technology, has been investigated in a Phase III clinical trial program (NCT01854645, NCT01854658, NCT01970878) in patients with COPD. Here, we present findings from a pharmacokinetic (PK) sub-study of NCT01854645 (PINNACLE-1).Methods: PINNACLE-1 was a multicenter, randomized, double-blind, parallel-group, 24 wk chronic-dosing, placebo- and active-controlled study. The PK sub-study assessed the systemic accumulation of glycopyrronium and formoterol following administration of GFF MDI 14.4/10 µg, GP MDI 14.4 µg, or FF MDI 10 µg (all BID) for 12 wks. Plasma for PK analysis was collected for up to 12 h after dosing, on Day 1 and Week 12.Results: Of 2,103 patients randomized in PINNACLE-1, 292 participated in the PK sub-study. The plasma concentration–time profiles of glycopyrronium were similar following treatment with GFF MDI or GP MDI, both after single dosing and at Week 12. Accumulation at Week 12 relative to Day 1 was up to 2.30-fold for glycopyrronium. The plasma concentration–time profiles of formoterol were similar following treatment with GFF MDI or FF MDI, both after single dosing and at Week 12. Accumulation at Week 12 relative to Day 1 was up to 1.62-fold for formoterol.Conclusion: Overall, the results have characterized the accumulation of glycopyrronium and formoterol associated with GFF MDI, GP MDI, and FF MDI, and indicated that there were no meaningful PK interactions, whether drug–drug or due to formulation, between glycopyrronium and formoterol following treatment with GFF MDI formulated using co-suspension delivery technology. Keywords: COPD, glycopyrronium, formoterol fumarate dihydrate, metered dose inhaler, co-suspension delivery technology, pharmacokinetics" @default.
• W2794357789 created "2018-03-29" @default.
• W2794357789 creator A5002603430 @default.
• W2794357789 creator A5011502862 @default.
• W2794357789 creator A5070315113 @default.
• W2794357789 creator A5075950948 @default.
• W2794357789 creator A5077419098 @default.
• W2794357789 creator A5077936927 @default.
• W2794357789 date "2018-03-01" @default.
• W2794357789 modified "2023-10-09" @default.
• W2794357789 title "Pharmacokinetics of glycopyrronium/formoterol <br />fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD" @default.
• W2794357789 cites W1890874870 @default.
• W2794357789 cites W1976421392 @default.
• W2794357789 cites W1980016322 @default.
• W2794357789 cites W2006528231 @default.
• W2794357789 cites W2014664741 @default.
• W2794357789 cites W2030987445 @default.
• W2794357789 cites W2056040906 @default.
• W2794357789 cites W2086199047 @default.
• W2794357789 cites W2142449488 @default.
• W2794357789 cites W2159837316 @default.
• W2794357789 cites W2163634883 @default.
• W2794357789 cites W2317895461 @default.
• W2794357789 cites W2558903543 @default.
• W2794357789 cites W2568255753 @default.
• W2794357789 cites W2591678263 @default.
• W2794357789 cites W2761239349 @default.
• W2794357789 doi "https://doi.org/10.2147/copd.s154988" @default.
• W2794357789 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5868634" @default.
• W2794357789 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29606861" @default.
• W2794357789 hasPublicationYear "2018" @default.
• W2794357789 type Work @default.
• W2794357789 sameAs 2794357789 @default.
• W2794357789 citedByCount "13" @default.
• W2794357789 countsByYear W27943577892018 @default.
• W2794357789 countsByYear W27943577892019 @default.
• W2794357789 countsByYear W27943577892020 @default.
• W2794357789 countsByYear W27943577892021 @default.
• W2794357789 countsByYear W27943577892022 @default.
• W2794357789 crossrefType "journal-article" @default.
• W2794357789 hasAuthorship W2794357789A5002603430 @default.
• W2794357789 hasAuthorship W2794357789A5011502862 @default.
• W2794357789 hasAuthorship W2794357789A5070315113 @default.
• W2794357789 hasAuthorship W2794357789A5075950948 @default.
• W2794357789 hasAuthorship W2794357789A5077419098 @default.
• W2794357789 hasAuthorship W2794357789A5077936927 @default.
• W2794357789 hasBestOaLocation W27943577891 @default.
• W2794357789 hasConcept C112705442 @default.
• W2794357789 hasConcept C126322002 @default.
• W2794357789 hasConcept C142724271 @default.
• W2794357789 hasConcept C197934379 @default.
• W2794357789 hasConcept C201645570 @default.
• W2794357789 hasConcept C204787440 @default.
• W2794357789 hasConcept C27081682 @default.
• W2794357789 hasConcept C2776017024 @default.
• W2794357789 hasConcept C2776042228 @default.
• W2794357789 hasConcept C2776136866 @default.
• W2794357789 hasConcept C2776780178 @default.
• W2794357789 hasConcept C2778375690 @default.
• W2794357789 hasConcept C2779871671 @default.
• W2794357789 hasConcept C2780261241 @default.
• W2794357789 hasConcept C2780667556 @default.
• W2794357789 hasConcept C2909086917 @default.
• W2794357789 hasConcept C509974204 @default.
• W2794357789 hasConcept C71924100 @default.
• W2794357789 hasConcept C98274493 @default.
• W2794357789 hasConceptScore W2794357789C112705442 @default.
• W2794357789 hasConceptScore W2794357789C126322002 @default.
• W2794357789 hasConceptScore W2794357789C142724271 @default.
• W2794357789 hasConceptScore W2794357789C197934379 @default.
• W2794357789 hasConceptScore W2794357789C201645570 @default.
• W2794357789 hasConceptScore W2794357789C204787440 @default.
• W2794357789 hasConceptScore W2794357789C27081682 @default.
• W2794357789 hasConceptScore W2794357789C2776017024 @default.
• W2794357789 hasConceptScore W2794357789C2776042228 @default.
• W2794357789 hasConceptScore W2794357789C2776136866 @default.
• W2794357789 hasConceptScore W2794357789C2776780178 @default.
• W2794357789 hasConceptScore W2794357789C2778375690 @default.
• W2794357789 hasConceptScore W2794357789C2779871671 @default.
• W2794357789 hasConceptScore W2794357789C2780261241 @default.
• W2794357789 hasConceptScore W2794357789C2780667556 @default.
• W2794357789 hasConceptScore W2794357789C2909086917 @default.
• W2794357789 hasConceptScore W2794357789C509974204 @default.
• W2794357789 hasConceptScore W2794357789C71924100 @default.
• W2794357789 hasConceptScore W2794357789C98274493 @default.
• W2794357789 hasLocation W27943577891 @default.
• W2794357789 hasLocation W27943577892 @default.
• W2794357789 hasLocation W27943577893 @default.
• W2794357789 hasLocation W27943577894 @default.
• W2794357789 hasOpenAccess W2794357789 @default.
• W2794357789 hasPrimaryLocation W27943577891 @default.
• W2794357789 hasRelatedWork W1990536820 @default.
• W2794357789 hasRelatedWork W2057984874 @default.
• W2794357789 hasRelatedWork W2092008657 @default.
• W2794357789 hasRelatedWork W2130094601 @default.
• W2794357789 hasRelatedWork W2165805239 @default.
• W2794357789 hasRelatedWork W2206295548 @default.
• W2794357789 hasRelatedWork W2558903543 @default.

• next